Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:businessModel |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Yin_Weidong
|
| gptkbp:country |
gptkb:China
|
| gptkbp:focus |
infectious diseases
human vaccines |
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Yin_Weidong
|
| gptkbp:headquarters_location |
gptkb:Beijing,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sinovac Biotech
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableEvent |
CoronaVac received emergency use authorization in multiple countries
CoronaVac included in WHO Emergency Use Listing |
| gptkbp:notableWork |
COVID-19 vaccine development
|
| gptkbp:numberOfEmployees |
over 1000
|
| gptkbp:product |
gptkb:CoronaVac
gptkb:Healive gptkb:Panflu gptkb:Panflu.1 Anflu |
| gptkbp:products |
vaccines
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SVA
|
| gptkbp:website |
http://www.sinovac.com
|
| gptkbp:bfsParent |
gptkb:CoronaVac
gptkb:Sinovac_COVID-19_vaccine |
| gptkbp:bfsLayer |
5
|